FIELD: chemistry.
SUBSTANCE: proposed group of inventions relates to the field of pharmacogenomics. Methods and a kit are disclosed for predicting the sensitivity of a patient with a malignant growth to treatment with a Wnt inhibitor by measuring the differential expression of a Notch1 biomarker in a sample of a malignant growth. Disclosed is the use of Wnt inhibitor 2-[5-methyl-6-(2-methylpyridin-4-yl)pyridin-3-yl]-N-[5-(pyrazin-2-yl)pyridin-2-yl]acetamide or a pharmaceutically acceptable salt thereof for the treatment of a patient with a malignant growth. Pharmaceutical compositions containing said inhibitor are disclosed.
EFFECT: proposed group of inventions provides effective determination of cell sensitivity to Wnt inhibitors by using specific biomarkers.
23 cl, 16 dwg, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SELECTION OF CANCER PATIENTS FOR INTRODUCTION OF WNT SIGNAL INHIBITORS BASED ON RNF43 MUTATION STATUS | 2013 |
|
RU2636000C2 |
| MEDICAL PREDICTION AND PREDICTION OF TREATMENT RESULTS USING ACTIVITY OF MULTIPLE CELL SIGNALING PATHWAYS | 2014 |
|
RU2718647C2 |
| DIAGNOSTIC TECHNIQUE FOR BREAST CANCER | 2013 |
|
RU2547583C2 |
| METHODS FOR TREATING MALIGNANT TUMOUR WITH APPLICATION OF NOTCH SIGNAL TRANSDUCTION PATHWAY INHIBITORS | 2008 |
|
RU2584579C2 |
| TREATING MALIGNANT TUMORS USING PIZ-KINASE ISOFORM MODULATORS | 2014 |
|
RU2705204C2 |
| TREATING MALIGNANT TUMOURS USING MODULATORS OF PI3-KINASE ISOFORMS | 2013 |
|
RU2702908C2 |
| THERAPY OF INTESTINAL ADENOMA AND/OR ADENOCARCINOMA BY INHIBITING NOTCH ACTIVATION | 2005 |
|
RU2392961C2 |
| INHIBITORS OF NOTCH SIGNAL TRANSMISSION WAYS AND THEIR APPLICATION FOR CANCER TREATMENT | 2012 |
|
RU2631611C2 |
| METHODS OF TREATING, DIAGNOSING AND PREDICTING A HEMATOLOGIC MALIGNANT NEOPLASM | 2015 |
|
RU2727418C2 |
| ANTIBODIES AGAINST NOTCH2 AND METHODS FOR APPLICATION THEREOF | 2009 |
|
RU2580029C2 |
